SavedAdd your journal

Journals / Uludağ Üniversitesi Tıp Fakültesi Dergisi / 2019 / Cilt: 45 - Sayı: 3

The Effect of Dapagliflozin on Platelet Function and Inflammation in Type 2 Diabetes

Tip 2 Diyabetli Hastalarda Dapagliflozin Tedavisinin Trombosit Fonksiyonları ve İnflamasyon Üzerine Etkisi

Mehmet Ali EREN
Çiğdem CİNDOĞLU
Burcu DİKEÇ GÖKÇE
Ali GÖKÇE
Tevfik SABUNCU
Pages
291–294
Publication Date
2019-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is a need to understand how and why this effect occurs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Dapagliflozin is an oral anti-diabetic drug (OAD) that has been shown to be safe and useful in cardiovascular diseases.
📊
Key Findings & Data:Laboratory data were recorded before and 3-6 months after the treatment of patients with type 2 diabetes over age of 18 years who received dapagliflozin when receiving OAD or OAD + insulin.
💡
Conclusion & Impact:There is a need to understand how and why this effect occurs.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Dapagliflozin · Ortalama Trombosit Hacmi · Nötrofil Lenfosit Oranı

Abstract

Dapagliflozin is an oral anti-diabetic drug (OAD) that has been shown to be safe and useful in cardiovascular diseases. The exact mechanism of cardiovascular positive effects of dapagiflozin is not fully understood. In this study, we aimed to investigate the effects of dapagliflozin treatment on mean platelet volume (MPV) as the marker of platelet function, and neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) as new anti-inflammatory markers. Laboratory data were recorded before and 3-6 months after the treatment of patients with type 2 diabetes over age of 18 years who received dapagliflozin when receiving OAD or OAD + insulin. Glucose and A1c values were significantly decreased (both p <0.001) and hemoglobin, hematocrit and NLR values were significantly increased with dapagliflozin treatment (p=0.005, p=0.001 and p=0.032, respectively). In addition, neutrophil count increased significantly and lymphocyte count decreased significantly (p=0.029 and p=0.019). Dapagliflozin is an effective OAD and affects inflammation in the body. There is a need to understand how and why this effect occurs.

Özet

Dapagliflozin kardiyovasküler hastalıklarda güvenli ve yararlı olduğu gösterilen bir oral anti-diyabetik (OAD) ilaçtır. Dapagliflozinin kardiyovasküler olumlu etkilerinin kesin mekanizması tam olarak bilinmemektedir. Bu çalışmada, dapagliflozin kullanan hastalarda tedavinin trombosit fonksiyonunu gösteren ortalama trombosit hacmi (OTH) ve yeni inflamatuar belirteçler olan nötrofil lenfosit oranı (NLO) ve trombosit lenfosit oranı (TLO) üzerine etkilerini araştırmayı amaçladık. Daha önce OAD veya OAD+insülin tedavisi almakta iken tedaviye dapagliflozin eklenen, 18 yaş üstü tip 2 diyabeti olan hastaların dosyaları incelenerek, dapagliflozin tedavisi başlamadan önce ve tedaviden sonra 3-6 ay içindeki laboratuar verileri kaydedildi. Dapagliflozin tedavisi ile birlikte glukoz ve A1c değerleri anlamlı olarak azalırken (her iki p<0.001), hemoglobin, hematokrit ve NLO değerleri anlamlı olarak arttı (sırasıyla p=0.005, p=0.001 ve p=0.032). Ayrıca nötrofil sayısı anlamlı olarak artarken, lenfosit sayısı anlamlı olarak azaldı (p=0.029 ve p=0.019). Dapagliflozin etkili bir OAD olup vücuttaki inflamasyon üzerine etkileri bulunmaktadır. Bu etkinin nasıl ve neden olduğunun anlaşılmasına ihtiyaç vardır.

🔖

Cite This Article

EREN, M. A., CİNDOĞLU, Ç., GÖKÇE, B. D., GÖKÇE, A., SABUNCU, T. (2019). The Effect of Dapagliflozin on Platelet Function and Inflammation in Type 2 Diabetes. Uludağ Üniversitesi Tıp Fakültesi Dergisi, Cilt: 45 - Sayı: 3, 291–294. https://ajindex.com/articles/134687

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. American Diabetes Association
  2. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41(Suppl 1):73-85
  3. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61(12):2461-98
  4. Lipscombe L, Booth G, Butalia S, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Diabetes Canada Clinical Practice Guidelines Expert Committee. Can J Diabetes 2018;42(1):88-103
  5. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo- controlled 102-week trial. BMC Med 2013;11:43
  6. Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs 2014;74(18):2191-209
  7. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996;7(2):157–61
  8. Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983;32(5):443–60
  9. Verdoia M, Schaffer A, Barbieri L, et al. Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. Diabetes Metab 2015;41(4):304-11
  10. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med 2012;5:2
  11. Li W, Liu Q, Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Sci Rep 2017;7:40426
  12. Atak B, Aktas G, Duman TT, Erkus E, Kocak MZ, Savli H. Diabetes control could through platelet-to-lymphocyte ratio in hemograms. Rev Assoc Med Bras (1992) 2019;65(1):38-42
  13. Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab 2018;20(2):344-51
  14. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2